In this study, we found CLEC12A aberrantly expressed on the CD34+CD38− cell compartment in 71% (22/31) of MDS patients, distributed across all Revised International Prognostic Scoring System risk groups. This evidence concerns the gene CLEC12A and myelodysplastic syndrome.